Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

KeyCorp Q4 Adj. EPS $0.48, Inline

byBenzinga Newsdesk

January 23, 2020

1 minute read

KeyCorp (NYSE:KEY) reported quarterly earnings of $0.48 per share which met the analyst consensus estimate. This is unchanged from the same period last year.

Morgan Stanley Maintains Equal-Weight on Pinnacle West Capital, Lowers Price Target to $73

By Benzinga Newsdesk

Today, 6:57 AM

Morgan Stanley maintains Pinnacle West Capital (NYSE:PNW) with a Equal-Weight and lowers the price target from $75 to $73.

PNW

Sinclair’s Q4 Revenue Misses Consensus Due To Cyber Incident, Absence Of Political Revenue; Hikes Dividend

By Anusuya Lahiri

Today, 6:57 AM

Sinclair Broadcast Group Inc (NASDAQ:SBGI) reported a fourth-quarter FY21 revenue decline of 2% year-on-year to $1.48 billion, missing the consensus of…

SBGI

FDA
News

Medtronic Announces FDA Approval Of Next-Gen TAVR System For Treatment Of Symptomatic Severe Aortic Stenosis

By Benzinga Newsdesk

Today, 6:57 AM

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR)

MDT

Avid Bioservices Q1 EPS $0.10 Beats $0.04 Estimate, Sales $30.80M Beat $27.81M Estimate

By Benzinga Newsdesk

Today, 6:57 AM

Avid Bioservices (NASDAQ:CDMO) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.04 by 150 percent. This is a 66.67 percent increase over earnings of $0.06 per share from the

CDMO

KeyCorp Q4 Adj. EPS $0.48, Inline

Related Posts

Morgan Stanley Maintains Equal-Weight on Pinnacle West Capital, Lowers Price Target to $73

Sinclair’s Q4 Revenue Misses Consensus Due To Cyber Incident, Absence Of Political Revenue; Hikes Dividend

Medtronic Announces FDA Approval Of Next-Gen TAVR System For Treatment Of Symptomatic Severe Aortic Stenosis

Avid Bioservices Q1 EPS $0.10 Beats $0.04 Estimate, Sales $30.80M Beat $27.81M Estimate